The U.S. Food and Drug Administration (FDA) has approved rofecoxib (Vioxx®), a Cox-2 selective inhibitor, for the relief of the signs and symptoms of the most common forms of JRA (pauciarticular or polyarticular) in children two years and older and who weigh at least 22 pounds. Juvenile rheumatoid arthritis (JRA) is a debilitating type of arthritis that can occur in throughout childhood. The FDA approval of Vioxx® for JRA was based on the largest JRA study ever conducted, which included 310 pediatric and adolescent patients aged 2 to 17 with active pauciarticular or polyarticular JRA.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.